Advantagene Launches "Proactive Surveillance™" Clinical Study in Patients with Localized Prostate Cancer Choosing Active Surveillance

***Auburndale, MA*, May 16, 2016 -** Advantagene, Inc., a clinical-stage biotechnology company developing a novel cancer immunotherapy platform for the treatment of solid tumors, announced today that it has treated the first patient in the ULYSSES study, a Phase 2b "Proactive Surveillance™" trial of its novel immuno-oncology product, ProstAtak®, in patients with localized prostate cancer choosing active surveillance. ProstAtak® is the trade name for the company's Gene Mediated Cytotoxic Immunotherapy (GMCI™) used in patients with prostate cancer. This multinational study is being conducted in the United States and in Mexico with collaborators Cellpharma, a regional pharmaceutical company, and the National Institute of Medical Sciences and Nutrition, Mexico.

"We are extremely excited to advance this potential treatment for patients that currently have no better alternative than to watch and wait" said Dr. Estuardo Aguilar-Cordova, Chief Executive Officer of Advantagene. "Successful development and commercialization of ProstAtak® will enable active surveillance patients to delay or reduce the need for radical surgery or radiation and have an enormous positive impact on the lives of hundreds of thousands of men each year around the world."

About the Study

The ULYSSES study is a multicenter, randomized, double blind, placebo-controlled study in prostate cancer patients choosing active surveillance. The study is designed to assess the efficacy of ProstAtak® compared to placebo and aims to enroll 156 patients. Eligible patients will be randomly assigned in a 2 to 1 ratio to the test arm or the control arm. The primary endpoint for the study is the percentage of patients with improvement in a composite active surveillance score based on prognostic tumor markers twelve months after treatment. The study will also evaluate multiple secondary endpoints to help better understand the immune response. For more information about the study, please visit www.clinicaltrials.gov and use reference identifier NCT02768363.

About Active Surveillance

The implementation of PSA screening programs has resulted in more than 50% of prostate cancer patients being diagnosed at early stages of disease. According to the Prostate Cancer Foundation, in 2015 there were nearly 221,000 men diagnosed and 28,000 deaths due to prostate cancer in the United States alone. Treatments for newly diagnosed localized prostate cancer include radical prostatectomy, radiation and androgen deprivation therapy. Since these treatments can have significant short and long-term side effects, including urinary incontinence and sexual dysfunction, postponing or avoiding treatment to preserve quality of life is of great interest. Under active surveillance, patients are managed with regular PSA and biopsy monitoring with the intent of pursuing radical treatment only when the disease progresses. The goal of active surveillance is to postpone or avert radical therapy to avoid its side effects. Active surveillance is currently recommended for men with low risk disease and is even an alternative for some men with

intermediate-high risk prostate cancer. Radical treatment is initiated in about 30% of active surveillance patients within 2-3 years of diagnosis due to Gleason grade, tumor volume and/or PSA progression or patient choice due to "PSA anxiety." If approved, ProstAtak® for Proactive Surveillance™ will provide patients with a low risk treatment option with the potential to delay or prevent disease progression without risk of incontinence or sexual dysfunction.

About Advantagene, Inc.

Advantagene is a Massachusetts based biotechnology company developing its proprietary Gene Mediated Cytotoxic Immunotherapy (GMCI™) platform technology for the treatment of solid tumors. GMCI™ is an "off the shelf" low toxicity immunotherapy that stimulates a patient's own immune system to generate a robust response against his or her individual cancer. Advantagene is conducting a registration clinical trial with its lead candidate, ProstAtak®, under a Special Protocol Assessment approved by the U.S. Food and Drug Administration, for the treatment of localized prostate cancer patients with intermediate to high risk disease choosing radiation therapy. If proven efficacious, ProstAtak® will be the first and only therapeutic pharmaceutical available for newly diagnosed localized prostate cancer patients. The company is conducting additional GMCI clinical studies in lung, pancreas and brain cancers with remarkable clinical results to date. For more information about Advantagene and our GMCI™ cancer immunotherapy program please visit www.advantagene.com.

Contact
Media & Investor Relations
Advantagene, Inc.
440 Lexington Avenue
Auburndale, MA 02466
(617) 916-5445
info@advantagene.com

Released May 16, 2016